| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2919 | 2017 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 1938 | 2017 |
| CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular … T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... Annals of Oncology 30, v874-v875, 2019 | 736 | 2019 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 676 | 2018 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... The Lancet Oncology 23 (1), 77-90, 2022 | 653 | 2022 |
| Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ... Clinical Cancer Research 25 (7), 2116-2126, 2019 | 463 | 2019 |
| Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ... Clinical Cancer Research 24 (17), 4154-4161, 2018 | 415 | 2018 |
| TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ... Cancer discovery 9 (8), 1064-1079, 2019 | 278 | 2019 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 276 | 2022 |
| Progression of RAS-mutant leukemia during RAF inhibitor treatment MK Callahan, R Rampal, JJ Harding, VM Klimek, YR Chung, T Merghoub, ... New England Journal of Medicine 367 (24), 2316-2321, 2012 | 263 | 2012 |
| Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression R Busch, CH Rinderknecht, S Roh, AW Lee, JJ Harding, T Burster, ... Immunological reviews 207 (1), 242-260, 2005 | 208 | 2005 |
| Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana‐Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan … JJ Luke, MK Callahan, MA Postow, E Romano, N Ramaiya, M Bluth, ... Cancer 119 (20), 3687-3695, 2013 | 200 | 2013 |
| First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting N Pandit-Taskar, MA Postow, MD Hellmann, JJ Harding, CA Barker, ... Journal of Nuclear Medicine 61 (4), 512-519, 2020 | 186 | 2020 |
| Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype MA Lowery, EJ Jordan, O Basturk, RN Ptashkin, A Zehir, MF Berger, ... Clinical Cancer Research 23 (20), 6094-6100, 2017 | 181 | 2017 |
| Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma GK Abou-Alfa, S Qin, BY Ryoo, SN Lu, CJ Yen, YH Feng, HY Lim, F Izzo, ... Annals of Oncology 29 (6), 1402-1408, 2018 | 176 | 2018 |
| Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection W Park, J Chen, JF Chou, AM Varghese, KH Yu, W Wong, M Capanu, ... Clinical Cancer Research 26 (13), 3239-3247, 2020 | 163 | 2020 |
| Ipilimumab for patients with advanced mucosal melanoma MA Postow, JJ Luke, MJ Bluth, N Ramaiya, KS Panageas, DP Lawrence, ... The oncologist 18 (6), 726-732, 2013 | 159 | 2013 |
| Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition JJ Harding, MA Lowery, AH Shih, JM Schvartzman, S Hou, C Famulare, ... Cancer discovery 8 (12), 1540-1547, 2018 | 158 | 2018 |
| Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a … A Cercek, T Boerner, BR Tan, JF Chou, M Gönen, TM Boucher, ... JAMA oncology 6 (1), 60-67, 2020 | 148 | 2020 |
| Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). GK Abou-Alfa, D Niedzwieski, JJ Knox, A Kaubisch, J Posey, BR Tan, ... Journal of Clinical Oncology 34 (15_suppl), 4003-4003, 2016 | 139 | 2016 |
Eileen M. O'ReillyMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
